HSPG2 and Dyskinesia: Furthermore, differences between OPC 50 mg vs. PLC in the increase from baseline in ON-time with troublesome dyskinesia were less in most of the subgroups of patients who were “earlier” in both their disease course and L-DOPA treatment pathway.